High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. by Nielsen, O. S. et al.
British Joumal ofCancer(1998) 78(12). 1634-1639
@199 Canoer Research Campaign
High-dose epirubicin is not an alternative to standard-
dose doxorubicin in the treatment of advanced soft
tissue sarcomas. A study of the EORTC soft tissue and
bone sarcoma group
OS Nielsen', P Dombemowsky2, H Mouridsen3, D Crowther4, J Verweij5, J Buesa6, W Steward7, S Daugaard8,
M van Glabbeke9, A Kirkpatrick9 and T Tursz'°
'Centre for Bone and Soft Tissue Sarcomas. Aarhus University Hospital. DK 8000 Aarhus C. Denmark: 2Department of Oncology. Copenhagen Unrversity
Hospital, DK 2730 Herlev, Denmark: 3The Finsen Center, Rigshospitalet. DK 2100 Copenhagen. Denmark: 4Department of Medical Oncology. Christie Hospital
NHS Trust, Manchester M20 4BX. UK: 5Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kiiniek) and University Hospital, 3008
AE Rotterdam, The Netherlands: 6Departrnent of Medical Oncology, Hospital General de Asturias. 36006 Ovieda. Spain: -Beatson Oncology Centre. Glasgow
G11 6 NT, UK: BIhe Laboratory Center. Rigshospitalet. DK 2100 Copenhagen. Denmark: 3EORTC Data Centre. 1200 Brussels. Belgium: ':Institut Gustave
Roussy, 94804 Villejuif Cedex. France
Summary The activty and toxicity of single-agent standard-dose doxorubicin were compared with that of two schedules of high-dose
epirubicin. A total of 334 chemonaive patients with histologically confirmed advanced soft-tissue sarcomas received (A) doxorubicin 75 mg m-2
on dcay 1 (112 patients), (B) epirubicin 150 mg m-2 on day 1 (111 patients) or (C) epirubicin 50 mg m-2 day-1 on days 1, 2 and 3 (111 patients);
all given as bolus injection at 3-week intervals. A median of four treatment cycles was given. Median age was 52 years (19-70 years) and
performance score 1 (0-2). Of 314 evaluable patients, 45 (14%) had an objective tumour response (eight complete response, 35 partial
response). There were no differences among the three groups. Median time to progression for groups A, B and C was 16, 14 and 12 weeks,
and median survival 45, 47 and 45 weeks respectively. Neither progression-free (P = 0.93) nor overall survival (P = 0.89) differed among the
three groups. After the first cycle oftherapy, two patients died of infection and one owing to cardiovascular disease, all on epirubicin. Both dose
schedules of epirubicin were more myelotoxic than doxorubicin. Cardiotoxicity (> grade 3) occurred in 1%, 0% and 2% respectively. Regardless
of the schedule, high-dose epirubicin is not a preferred alternative to standard-dose doxorubicin in the treatment of patients with advanced soft-
tissue sarcomas.
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In the primary treatment of adult soft-tissue sarcomas. local treat-
ments xxith surgen and adjuxant radiotherapy are essential for
achievinc long-term survixal (Robinson. 1994: Suit. 1995).
Hoxexver. despite optimal local treatment of the primarv tumour.
disseminated disease will dexelop in many patients. Consequently.
chemotherapy has been extensively studied in soft-tissue sarcomas
(Suit et al. 1995: Verxxeij et al. 1995). Unfortunately. their respon-
sixeness to chemotherapy has been disappointinglx low.
Although doxorubicin was one of the first agents reported to
haxe actixitv (Gottlieb et al. 1975). it still appears to be one of the
most active drugs in the treatment ofsoft-tissue sarcomas (Verweij
et al. 1995). Txxo other drugs with demonstrated first-line activitx
in soft-tissue sarcomas are ifosfamide and dacarbazine (Verweij et
al. 1995). During the last decade. more than 2000 patients haxe
been treated with doxorubicin as a single agent. with reported
response rates in non-pretreated patients ofabout 25%7 (O'Brvan et
al. 1973: Borden et al. 1975: Mouridsen et al. 1987: Verweij et al.
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1995). Activitx has also been obserx ed in pretreated patients
(Blackledge et al. 1990). Although their study desigyn has been
criticized. O'Brvan et al (1973) have indicated a strong
dose-response relationship for doxorubicin. To obtain optimal
response rates. a dose of at least 70 mg m-' evenr 3 wxeeks appears
to be necessary.
Oxer the last 20 y-ears. the EORTC Soft Tissue and Bone
Sarcoma Group (STBSG) has investigated different drug combi-
nations as first-line chemotherapy in several randomized trials
(Verweij et al. 1995). In those studies. no regimen has demon-
strated any advantage in terms ofresponse rate as well as progres-
sion-free and overall sun,ixal compared x-ith single-agent
doxorubicin 75 mg m-' given even 3 weeks (Verxeij et al. 1995:
Santoro et al. 1995). Therefore. the EORTC STBSG presently
considers single-agent doxorubicin as the standard treatment for
advanced soft tissue sarcomas.
Treatment duration with doxorubicin is limited because of its
cumulative cardiotoxicitv. It is. therefore. important to test anthra-
cycline analoaues x-ith potentially less toxicity and equal or better
actixity. Howxexver. at present. only a fexx analogues haxe been
ex aluated in studies x ith an adequate number of patients.
Carminomycin and mitoxantrone. as well as other analorues. haxe
been shown to be inactixe (Bramxell et al. 1983: Bull et al. 1985:
Suit et al. 1995). In a randomized study comparing doxorubicin
1634Epirubicin vs doxorubicin in soft bissue sarcomas 1635
and epirubicin both at a dose of 75 mg m-'2 no difference in
survival and duration ofresponse was found. and the response rate
was only slightly in favourofdoxorubicin (Mouridsen et al, 1987).
However, this was achieved at the expense oftoxicity, which was
significantly more pronounced for doxorubicin. These data indi-
cate that epirubicin may be less toxic than doxorubicin when
administered in equipotent doses. Consequently, increasing the
epirubicin dose could lead to a greater antineoplastic effect with
acceptable toxicity. It is now known that much higher doses of
epirubicin can be applied (Chevalier et al, 1990; Jelic et al. 1990:
Plosker and Faulds, 1993). Moreover, at the time of starting the
present study, it was believed that alterations in the pharmaco-
kinetic principles could result in enhanced treatment efficacy
without or with only minor alterations in toxicity. Cardiac toxicity
may be related to the peak concentration of the drug, and lower
toxicity could. therefore, be expected with fractionated schedules
compared with high-dose epirubicin given as a bolus injection. In
view of this, the EORTC STBSG initiated a randomized phase 3
study comparing standard-dose doxorubicin 75 mg m-2 with two
schedules of high-dose epirubicin. either 150 mg m-2 as a single
bolus or 50 mg m-2 day-' bolus injection for 3 consecutive days.
The present report gives the final results ofthis study.
MATERIALS AND METHODS
Eligibility criteria
This study was conducted in patients with histologically proven
soft tissue sarcomas. who either had relapsed locally or developed
metastases after primary surgery and/or radiotherapy or who
initially presented with advanced inoperable disease. Patients who
had received priorchemotherapy, whether as adjuvant reatment or
for advanced disease. were not eligible. Other eligibility criteria
included: age between 18 and 70 years, performance status 0-2 on
the WHO scale (Doyle et al. 1993), nohistory ofsignificant cardio-
vascular disease. no prior malignant tumour (except for adequately
treated carcinoma in situ of the cervix and/or carcinoma of the
skin), no CNS metastases, nonnal creatinine (< 150 tmol 1').
bilirubin (< 25 jmol 1-'), leucocytes (> 3.5 x 1091-1) and thombo-
cyte counts (> 100 x 10911) at entry. and presence of measurable
lesions not previously irradiated. Patients with mesothelioma.
chondrosarcoma, neuroblastoma. osteosarcoma. Ewing's sarcoma.
embryonal rhabdomyosarcoma and dermatofibrosarcoma protu-
berans were excluded. Informed consent was obtained from all
patients according to local and/or national rules.
Design of trial
The study aimed to compare time to progression. survival, response
rate and response duration. as well as acute and chronic toxicity.
Patients were stratified by institution and by performance status
(WHO 0, 1. 2). Patients fulfilling the inclusion criteria were
randomly allocatedby the EORTC DataCentre toreceive treatment
with doxorubicin or one oftwo schedules ofhigh-dose epirubicin.
Therapeutic regimens
Patients were initially randomized to receive (a) an i.v. bolus injec-
tion ofdoxorubicin 75 mg m-2 every 3 weeks, or(b) epirubicin at a
dose of either 160 mg m-2 as a single i.v. bolus injection or (c)
three i.v. bolus injections of 60 mg m-2 on days 1. 2 and 3. both
repeated every 3 weeks. The last two dose schedules had been
reported to be feasible by others (Chevalier et al. 1988; Jelic et al,
1990). Because of severe and lethal neutropenia in the first
patients. the epirubicin doses were reduced to 150 mg m-2 and 3 x
50 mg m-2 day-'. respectively. and administered as a 30-min i.v.
infusion. Only 20 patients (28 cycles) received the higher doses.
Dose modificatios
The evaluation oftoxicity was carried out according to the recom-
mendation made by WHO for grading ofacute and subacute toxic
effects. In patients with haematological toxicity WHO grade 1 and
2 at the start of the next cycle. the treatment was postponed for 1
week. Ifthe start ofa cycle was postponed by more than 3 weeks.
the patient went offstudy. In case ofnadir WBC < 0.5 x 109 1-1 (or
< 1.0 x 109 1-1 + infection) and/or platelets < 50 x 1091-'. the drug
dose was reducedby 20%. In case ofa decrease in cardiac ejection
fraction to < 50% at rest or < 60% at maximal exercise. it was at
the discretion ofthe investigator to stop treatment. If grade 3 or 4
mucositis occurred. the dose was reduced by 20%.
Treatment duration
At least two cycles were given. except in the case of rapid disease
progression. The maximal accepted cumulative dose was
550 mg m-2 fordoxorubicin and 1000 mg m- forepirubicin. When
six cycles ofchemotherapy had been administered and the cumula-
tive dose achieved. two additional cycles couldbe given atthe deci-
sion of the clinician. Patients achieving a complete response were
recommended to continue treatment for at least two more cycles
until the maximum cumulative dose was reached. Otherwise.
patients continued treamnt until disease progression. maximum
cumulative dose, unacceptable toxicities orpatient refusal.
Pretreatment and follow-up evaluations
Evaluation before treatment included history and clinical examina-
tion. performance status, tumour measurements (computerized
tomography or ultrasound scans). haematology (haemoglobin.
WBC. platelet counts). blood chemistry (urea. electrolytes. creati-
nine, calcium. bilirubin. alkaline phosphatase. aspartate amino-
transferase (ASAT) or alanine aminotransferase (ALAT), lactate
dehydrogenase, plain chest radiograph. electrocardiogram (ECG).
bone scan and/orradiograph (optional). andcardiac (radio nuclide)
ejection fraction. Blood counts were performed weekly during
teatmnt for the initial two treatment cycles. At follow-up. clin-
ical examination as well as blood counts and chemistries were
performed before every cycle. Chest radiograph, tumour measure-
ments, ECG and cardiac ejection fraction (optional) were carried
out every second course. In patients receiving more than six
cycles. the cardiac ejection fraction was measured before each
treatment.
Definition of response
Patients were considered assessable for response if they had
received at least two cycles of chemotherapy. Response was
defined according to the WHO criteria. Progression-free and
overall survival were computed from the date of randomization.
The period ofoverall response was computed from the first day of
treatment to the date of first observation of progressive disease.
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Table I Patient characteristics
hacIeistc Dox r-in iiLibin Epfibicin
I day 3days
Registered patents 112 111 111
Ineligie pabents 7 5 3
lrmuffickie data 1 2 2
Induded pabents 104 104 106
Median age, years (range) 52 (20-62) 55 (23-73) 47 (19-70)
Men (%) 51 (49) 53(49) 50(47)
Women(%) 53(51) 51 (51) 56(53)
Performce status
0 ()32 (31) 37 (36) 33 (31)
1(%) 57 (55) 50 (48) 58 (55)
2(%) 15(14) 17(16) 15(14)
Hisologcl grade
1 (%) 22(21) 18(17) 25(24)
2(%) 38 (37) 50 (48) 36 (34)
3(%) 44 (42) 36 (35) 45 (42)
Lungmetasases(%) 49 (47) 49 (47) 54 (51)
Liver (%) 22 (21) 20 (19) 19 (18)
Bone netstses (%) 7 (7) 4 (4) 10 (9)
The periodofcomplete response (CR) lasted from the date CR was
first recorded to the date ofprogression. Patients progressing after
one cycle were classified as treatment failures. Patients taken off
study after one cycle because oftoxicity were considered inevalu-
able forresponse, but remained evaluable fortoxicity.
Stas_l conskeraoo
The aim ofthe trial was to evaluate whether the 30% response rate
obtained in the previous trial of our group with standard-dose
doxorubicin could be increased to 45% with one oftwo high-dose
epirubicin regimens. The tral was conducted in two phases. In the
first part, a total of 30 patients was randomized in each treatment
arm, and the data analysed as a randomized phase II trial. As the
toxicity and the numberofresponses in the epirubicin groups were
acceptable after the dose reduction after the first 20 patients were
entered, the trial was continued as planned as aphase EII study. For
this purpose, 100 additional patients in each treatment group had
to be randomized. This would enable the detection of a 15%
increase in a response rate (a = 0.05,0 = 0.2, one tailed).
Because ofdecrease in the recruitment rate, an interim analysis
was perforned and discussed with an Independent Data
Monitoring Committee. The Committee decided to stop recruit-
ment and publish the data because of the high toxicity profile of
the Epirubicin groups and their lack of improvement in response
rate, making also an improvement in time to progression oroverall
survival unlikely. At that stage, the sample size was sufficient to
detect the 15% increase in response rate between the two epiru-
bicin groups analysed together and the doxorubicin group.
The 20 patients who received the higher doses of epirubicin
(160 mgm-2 and 60 mg m-2 x3) are included in all analyses. Thus,
the paper is based on all 334 randomized patients including the 90
patients ofthe phase H study, ofwhich 314 patients were eligible.
Exact 95% confidence intervals for proportions were calculated
for response rates. Duration of response, progression-free and
overall survival were estimated by use of the Kaplan-Meier
Table 2 Dose intensty parametersa
Doxonubic Epirubicin Epirubicin
I day 3 days
Cycles 4 (1-8) 4 (1-11) 4 (1-9)
Total dose (mg rn 2) 299 (50-599) 592 (131-1343) 481 (50-1105)
Duraton (days) 84 (21-218) 100 (21-230) 84 (21-232)
Relaibve dose intensity (%) 97 (67-114) 94 (52-107) 92 (3-120)
aecian (range).
method (Kaplan and Meier, 1958). The log-rank test was used for
comparison between survival curves (Peto et al, 1977).
Quality contro
A central pathology panel reviewed and graded histopathological
material from patients entering the trial, according to the rules of
the EORTC STBSG. Similarly, all responding patients underwent
an independent external response review according to the rules of
EORTC STBSG. The quality control of the group has been
described elsewhere (Vantongelen et al, 1989).
RESULTS
Paten chaacte sUcs
A total of 334 patients from 34 centres were included. Fifteen
patients were considered as ineligible forthe trial forthe following
reasons: ineligible type of sarcoma (n = 6), histology other than
sarcomas (n = 2), no target lesion (n = 1), concurrent disease (n =
2), age > 70 years (n = 1), performance status > 2 (n = 1), prior
breast cancer(n = 1) andpriorchemotherapy (n = 1). An additional
five patients were lost during follow-up. In total, 20 patients were
excluded from the analysis, which consequently was based on 314
patients (Table 1).
Covariates were evenly distributed among the three treatment
groups with regard to age, sex, performance status, histological
grades, sites of involvement, and prior treatment (Table 1). Only
20% of the patients were younger than 40 years, and 25% were
older than 60 years. Bone metastases were reported for 7% of the
patients, but this was not systematically investigated because bone
metastases were not permitted as measurable disease.
A central histopathology review was performed in 265 (83%) of
the patients. In the three treatment groups (doxorubicin, 1-day
epirubicin and 3-day epirubicin), leiomyosarcomas contributed
41%, 41% and 38%, respectively, whereas liposarcomas
contributed 13%, 12% and 8% and malignant fibrous histiocytoma
10%, 11% and 10% respectively. Theotherhistopathological types
were equally distributed among the other patients (data not
shown). Prior radiotherapy was given to 69 (22%) ofthe patients.
Trea_tmet compliance
Treatmnt compliance did not differ among the three treatment
groups. Thepatients received amedian offourcycles, rangingfrom 0
to 11 cycles. Only six patients received more than eight cycles. In all
but one, the dose had been reduced at an earlier stage, and, therefore,
they did not receive more than 1200 mg m-2 epiubin One patent
received nine cycles at full dose, and a total dose of 1316 mg m-2
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Table 3 Haematological toxicity
WHO grade Doxorubicin Epirubicin Epirubicin
(%) 1 day (%) 3 days (%)
Leucopenia
Grade 3/4 38 (38) 64 (63) 76 (75)
Grade 4 8 (8) 26 (26) 33 (32)
Neutropenia
Grade 3/4 41 (51) 58 (73) 61 (77)
Grade 4 17 (21) 42 (53) 55 (70)
Thrombocytopenia
Grade 3/4 2 (2) 14 (14) 18 (18)
Grade4 0 3 (3) 5 (5)
Table 4 Non-haernatological toxicity
WHO grade Doxorubicin Epirubicin Epirubicin
(%) 1 day(%) 3 days (%)
Haemorrhage
Grade 3/4 0 1(1) 1(1)
Grade 4 0 0 0
Infection
Grade 3/4 3 (3) 8 (8) 15 (14)
Grade4 1 (1) 3(3) 5(5)a
Nausea/vomiting
Grade3/4 13(13) 23(22) 12(11)
Grade4 3 (2) 2 (2) 2 (2)
Local reaction
Grade3/4 1 (1) 10 (10) 10 (10)
Grade4 0 2 (2) 3 (3)
Skin reaction
Grade 3/4 0 1(1) 1(1)
Grade4 0 1(1) 0
Mucostis
Grade3/4 6(6) 15(15) 14(15)
Grade4 2 (2) 2 (2) 4 (4)a
Cardiotoxicity
Grade 3/4 1(1) 0 2 (2)
Grade4 0 0 2 (2),
aTwo patients died of infection (grade 4 leucopenia + mucositis): tone patient
died of cardiovascular disease.
epirubicin (1-day regimen). The majorty of the patients received a
maximum of6 or 7 cycles. Two patients refused the first cycle ofthe
treatment. The reason for stopping therapy was progression of
disease in 50%7c. cumulative dose reached in 26%. toxicitv in 9%7.
patient refusal in 6%. intercurrent death in 2% and other reasons in
7%7 of the patients. Three early toxic deaths were reported. all in the
3-day epirubicin schedule group after the first cycle: two of infec-
tion/mucositis (dose. 150 mg m-' and 180 mg m-') and one ofcardio-
vascular disease (150mg m m).
The dose intensity was computed according to the Hrvniuk
method (Hrnniuk and Bush. 1984). Dose intensity parameters are
summarized in Table 2. The total treatment duration Awas computed
as the difference between the first and last day of administration.
plus 21 days. corresponding to the theoretical duration of the last
cycle. The 20 patients receiving, the higher doses of epirubicin
(160 mg m- and 60 mg, m-' x 3) are included in all dose intensitv
analyses. In the computation of the relative dose intensity'. these
higher doses were compared with the 150-mg, m-' reference. which
explains the maximum relative dose intensity of 107% and 120%7
in these two groups. The decrease in dose intensity was apparentlI
due to dose reductions in the 3-day epirubicin schedule group. and
treatment delays in the 1-day epirubicin schedule group.
Toxicity
The tmo patients who did not receive any treatment Aere excluded
from all toxicitv analyses. The haematological toxicities expressed
as the lowest value of haematological counts observed during the
whole treatment are presented in Table 3. and. thus. represent the
worst toxicityN observed dunng therapy. The haematological toxi-
city obsened w-ith the two regimens ofepirubicin was more severe
compared with doxorubicin in terms of leucopenia. neutropenia
and thrombocy-topenia (P < 0.0005). No significant difference A-as
observed between the two epirubicin schedule groups (P > 0.19).
Apart from infection. mucositis and vomiting. *enr few grade 3
and 4 toxicities were observed (Table 4). When compared with
doxorubicin. the two epirubicin treatment groups demonstrated a
significantly higher rate of infection [P = 0.026 (1-day schedule)
and P = 0.007 (3-day schedule]. whereas the increase in mucositis
was not statistically significant (P = 0.53 and P = 0.09). In addition.
the followinc,grade 3 side-effects were observed with the 1-day and
P = 0.93 (log rank test)
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Figure 1 Actuanal estimate of progression-free survival of patients with soft-tissue sarcoma randomized to doxorubicin 75 mg m-2 on day 1. epirubicin
150 mg m-2 on day 1. or epirubicin 50 mg m-2 on days 1.2 and 3, every 3 weeks. No significant difference was seen between the three schedules
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P=0.89 (log rank test)
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Figure 2 Actuanal estimate of overall surival of patients with soft-tissue sarcoma randomized to doxorubicin 75 mg m-2 on day 1. epirubicin 150 mg m-2 on
day 1. or epirubicin 50 mg m-2 on days 1. 2 and 3, every 3 weeks. No significant difference was seen between the three schedules
Table 5 Response to treatment
Doxorubicin Epirubicin Epirubicin Total (%)
(%) 1 day (%) 3days(%)
CR 2 (2) 3 (3) 3 (3) 8 (3)
PR 12 (12) 12 (12) 11 (11) 35 (11)
NC 52 (50) 46 (43) 41 (39) 139 (44)
PD 38 (36) 43 (41) 46 (43) 127 (40)
NE - - 5 (5) 5 (2)
CR. complete response; PR, partial response; NC. no change: PD.
progressive disease; NE, not evaluable.
3-day epirubicin schedules respectixely: diarrhoea in tuo and three
cases. and drug fexer in one and one cases. In the 3-day epirubicin
group. three toxic deaths were reported: two patients died of
neutropenic infection (dose = 150 mcn m-' and 180 m, m-') and one
patient died ofcardiovascular disease (dose = 150 mg m-') after one
cycle. In the doxorubicin group. one patient died because of
cardiotoxicits after eight cvcles. His cardiac ejection rate (LVEF at
rest) had dropped from 70%7 to 20% between the fifth and the
eighth cycle (initial value 74%). As this patient died 3 months after
the end oftherapy. cardiotoxicity has not been reported as an acute.
but as a late. side-effect.
Survival
Progression-free sun-ixal curves are show-n in Figure 1. When
progression was reported on the first measurement form after two
treatment cycles, the case was considered as a failure from the
onset oftreatment. This explains why the curves do notoriginate at
100%e. Patients who died in remission or with stable disease were
censored at the date ofdeath.
In the three treatment groups (doxorubicin. 1-day epirubicin and
3-day epirubicin). the 1-yearprogression-free estimates were 13c.
12% and 18%. respectivelv. and the 2-year estimates 4%. 4%cand
7% respectively. The standard error on all these estimates was less
than 5%. No statistically sirnificant difference Aas observed
between the groups (P = 0.93). The median follow-up w-as 3 years
(actuarial estimate.) and only 48 patients were still alive at the time
ofthe data analvsis.
The estimated median duration of surnival was 45 weeks in the
doxorubicin group. 47 xxeeks in the 1-day epirubicin group. and
45 weeks in the 3-day epirubicin schedule group (Figure 2). The
standard error was equal to or lower than 5%c for all estimates. The
1-vear sunrixal estimates in the three treatment groups xxere 45%7.
43%7 and 45%. respecti-ely. and the 2-year estimates 17%. 17%
and 189% respectively. No statistically significant difference was
obserned among the three groups (P = 0.89).
Response
The overall response data are shown in Table 5. All responses hax-e
been externally rexiexxed and all cases exaluated by the study
coordinator. The 'progression' category includes early progres-
sions as well as early' deaths due to malignant disease. A total of
five patients wxere unexaluable because of early death due to
infection (two patients). cardioxvascular disease (one patient) and
pulmonary embolism (to o patients) in the 3-day epirubicin
schedule. The patient who died of cardiox ascular disease after the
first cycle had already showxn progression on the chest radiograph
and w as. therefore. included in the 'progression' category.
There wxas no difference in response rates among the three
groups. The oxerall response rates [CR + partial response (PR)]
were 14% [95%s confidence interval (95%7 CI) 7-22%c] in the
doxorubicin group. 15% (8-23%/) in the 1-day epirubicin schedule
group and 14% (6-20%) in the 3-day epirubicin schedule group.
The median time to progression in the three groups was 16. 14 and
12 wxeeks respectively.
DISCUSSION
A previous study by our group has shoxx-n that equimolar doses of
doxorubicin and epirubicin in advanced soft-tissue sarcomas
produced response rates which did not differ significantlv. but with
more pronounced toxicity after doxorubicin (Mouridsen et al.
1987.) In the present study'. tx o schedules of high-dose epirubicin
ere tested with the aim of increasing the efficacv hile still main-
taining acceptable toxicity. How'ever. despite a significant increase
in both haematological and non-haematolorical acute side-effects.
neither of the two high-dose schedules demonstrated any superior
outcome compared w-ith standard-dose doxorubicin.
Both the median time to progression and the median surnixal
were similar to those obtained in prexious trials performed by the
EORTC-STBSG in comparable patients. Howexer. the response
rate obtained in the present study is disappointinr and lower than
that previouslV reported - a trend that has been found in many
studies. For example. in our group. doxorubicin gaxe response
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rates of 29% in 1983 (Bramwell et al, 1983). 25% im 1987
(Mouridsen et al. 1987). 22% in 1995 (Santoro et al, 1996) and
14% in the present study. We found a relative dose intensity of
doxorubicin of97% (Table 2). Thus, inadequate dose intensity was
not the reason for the poor response rate. In rare diseases such as
soft-tissue sarcomas, patient selection may give variations in the
reported response rates. Thus, to understand the low response rate,
the known prognostic factors forresponse were compared between
the present study and two other large trials ofour group (Pinedo et
al. 1984; Santoro et al, 1995). Neither variation in the proportion
of liver metastases nor the median age fully explained the
observed difference in response rates. In the present study, the
number of leiomyosarcomas was slightly higher than that of
previous studies, and we are presently analysing to what extent
this change in histological frequencies may explain the low
response rate. Finally, a more rigid assessment of response may
also contribute to the falling response rates - an explanation that is
also currently being investigated.
Four randomized studies have been performed by ECOG and
EORTC comparing single-agent doxorubicin with different
combination chemotherapy regimnens (Edmonson et al, 1993;
Verweij et al, 1995). Although the response rates were slightly
higher for some of the combination chemotherapy regimens, they
were not associated with an improved survival. Tberefore, it has
been concluded that standard-dose doxorubicin is as effective as
combination chemotherapy (Santoro et al, 1995; Verweij et al,
1995), and the disappointingly low response rates obtained in the
present study once again stresses the primary resistance of soft-
tissue sarcomas to chemotherapy and the need for new active
drugs. Unfortunately, there is a generl lack ofinformation on the
mechanisms ofdrug resistance in this disease.
In conclusion, regardless of the schedule, high-dose epirubicin
did not increase progression-free survival, overall survival or
response rate compared with standard-dose doxorubicin. We
recommend that on the basis of equivalent efficacy, but reduced
toxicity and expense, standard-dose doxorubicin is the preferred
anthracycine in advanced soft-tissue sarcoma, as compared with
high-dose epirubicin.
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